泰国草药配方治疗认知障碍的治疗潜力:综合洞察的代谢学方法
Pravit Akarasereenont1,2,3, Saracha Pattanapholkornsakul1, Suveerawan Limsuvan1
1Center of Applied Thai Traditional Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, 10700, Bangkok, Thailand.
Heliyon
|April 1, 2024
概括
泰国草药Yahom no.20 (YHF20) 可能会改变慢性脑性缺血 (hypoperfusion) 中的代谢物,这是一种与血管性痴呆症相关的疾病. 这项研究发现,YHF20影响了谷氨的新陈代谢,但没有影响大鼠的记忆力或引起毒性.
科学领域:
- 神经科学和药理学 神经科学和药理学
- 代谢学和草药医学研究研究
背景情况:
- 慢性脑性缺血低流与血管性痴呆的发病有关,其特征是代谢变化.
- 目前对血管性痴呆症的治疗方法有限,这凸显了对新型治疗策略的需求.
- 泰国草药Yahom no.20 (YHF20) 对疲劳和头有传统的用途,其成分可能与大脑缺血有关.
研究的目的:
- 在慢性脑性缺血低输液的老鼠模型中,研究YHF20给药引起的代谢变化.
- 评估YHF20在脑缺血的情况下对空间学习和记忆的影响.
- 在实验模型中评估YHF20的潜在肝毒性和毒性.
主要方法:
- 在Wistar大鼠中使用永久双侧常见动脉封闭 (2-VO) 来确立慢性脑性缺血低输液.
- 每天给予YHF20 (100,300或1000毫克/公斤) 或载体,持续56天.
- 通过LC-MS/QTof进行血代谢组分析,使用莫里斯水迷宫进行空间学习/记忆评估以及毒性研究.
主要成果:
- 慢性大脑低 perfusion 改变了78个已知的代谢物和10个暂定的途径.
- 在缺血状态下,YHF20的使用显示出对谷氨和谷氨代谢的潜在影响.
- 没有观察到对空间学习和记忆的显著影响,56天后也没有检测到肝毒性或毒性.
结论:
- 服用YHF20可能会诱导与脑缺血相关的代谢变化,但不会对认知功能或器官毒性产生不良影响.
- 特定代谢物的变化可能与YHF20的成分有关,需要进一步调查以进行质量控制.
- 这些发现提供了初步数据,支持YHF20在调节脑缺血中的代谢途径中的作用,有助于理解痴呆症的发病因子.
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
122
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
122
01:22Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184
01:26Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469